P2RY12 and acute coronary syndrome: For patients with non-ST segment elevation acute coronary syndrome, results of a subsequent meta-analysis of 4 RCTs indicated that a novel P2Y12 antiplatelet was associated with a significantly reduced rate of MACE compared with clopidogrel (risk ratio [RR] = 0.87), but the incidences of major and minor bleeding events were significantly higher (RR = 1.27, 1.20) [14].